Testosterone Undecanoate and Alcohol: Why the Combination Is Dangerous
Testosterone undecanoate is the longest-acting ester among the injectable forms and, at the same time, the basis of several oral drugs. Unlike other esters, it is almost always used in a medical context — for replacement therapy in men with hypogonadism. That is why the question of alcohol here sounds like this: how does drinking affect the treatment, the safety of procedures, and the monitoring of therapy. The editorial team examines both forms separately.
Two Forms of Undecanoate — Two Different Situations
Undecanoate is a testosterone ester with undecanoic acid, which contains eleven carbon atoms. The long lipophilic “tail” makes it possible to create both injectable depot drugs with a very long action and oral capsules, in which the hormone is absorbed together with fats through the lymphatic system, partly bypassing first-pass metabolism in the liver.
Injectable undecanoate is known under the trade names Nebido in Europe and Aveed in the USA. According to the instructions, after an initial period with a shorter interval, injections are given approximately once every 10–14 weeks. The drug is administered slowly, deep into the muscle, and only by medical personnel.
The oral forms are the older capsules, which should be taken with food, and newer drugs approved by the FDA in recent years. For the newer oral forms, the labeling carries a boxed warning about increased blood pressure. This is important in the context of alcohol, which we will return to below.
No direct pharmacological interaction of undecanoate with ethanol has been described. However, each form has its own points of intersection with alcohol: for the injectable one it is the safety of the procedure and the long-lasting depot, for the oral one it is absorption and blood pressure, and for both it is the effect of alcohol on the very cause for which the therapy was prescribed.
| Parameter | Injectable undecanoate | Oral undecanoate |
|---|---|---|
| Frequency of use | Once every 10–14 weeks (after the initial phase) | Daily, with food |
| Who administers it | Medical personnel | The patient independently |
| Special warnings in the labeling | Oil-solution microembolism, anaphylaxis (Aveed) | Increased blood pressure (newer forms) |
| Key point of intersection with alcohol | Long-lasting depot, the patient’s condition on the day of the procedure | Blood pressure, the regimen of taking with food |
Alcohol as a Cause of Low Testosterone
Before talking about interaction with the drug, it is worth recalling: excessive alcohol consumption in itself lowers testosterone levels. The review by Emanuele and Emanuele (1998) describes the direct toxic effect of ethanol on Leydig cells, disruption of regulation at the level of the hypothalamus and pituitary, and changes in the metabolism of sex hormones in the liver.
The Endocrine Society clinical guidelines (2018) require, before prescribing therapy, confirming the hormone deficiency with repeated morning tests and clarifying its cause. Functional hypogonadism caused by reversible factors — obesity, some medications, excessive alcohol consumption — may improve after these factors are removed.
In practice this means that in some men low testosterone is not an independent disease but a consequence of lifestyle. If such a person receives undecanoate but continues to drink heavily, the therapy “masks” the problem without removing its cause, and the risks of alcohol to the liver, heart, and psyche remain.
That is why the doctor asks about alcohol consumption at the first consultation, and the answer must be honest. The diagnosis, the choice of treatment, and which parameters will need to be monitored especially carefully all depend on it.
The Injectable Form: A Depot for Months and the Day of the Procedure
A single injection of undecanoate maintains the hormone level for weeks, so any alcohol consumption during this period takes place against the background of a stable depot. It is impossible to “wait out” the action of the drug, and it is worth discussing with the doctor the total amount of alcohol rather than tying it to the date of the injection.
At the same time, the day of the procedure itself is of particular importance. The Aveed labeling notes the risk of serious reactions immediately after the injection: pulmonary oil microembolism (POME), which manifests as coughing, shortness of breath, throat tightness, and chest pain, as well as anaphylaxis. Because of this, in the USA the drug is administered only in certified facilities under a special safety program, and the patient is observed for 30 minutes after the injection.
The guidelines have no separate requirement regarding alcohol before the procedure, but for safety reasons the editorial team considers it sensible to come to the injection sober. Intoxication can make it harder both for the patient to assess their well-being and for staff to recognize early symptoms of a reaction, and alcohol itself affects blood pressure and heart rate.
The large volume of the oil-solution injection also means a risk of local reactions — pain, hematomas. Alcohol dilates blood vessels and affects clotting, so heavy consumption immediately before or after the procedure is undesirable for this reason too.
The Oral Form: Absorption and Blood Pressure
Oral undecanoate is absorbed together with dietary fats through the lymphatic system, which is why the instructions require taking the capsules with food. The effect of alcohol on this process has not, as far as the editorial team knows, been specifically studied in controlled trials. We cannot claim that alcohol increases or decreases absorption — such claims on the internet have no evidence base.
The practical risk is different: irregular eating, missed doses, and confusion with dosing, which often accompany heavy feasts. For a drug whose effectiveness depends on being taken with food, this can mean an unstable hormone level.
The main point of intersection is blood pressure. In the labeling of the newer oral forms of undecanoate, the FDA requires a warning about increased blood pressure, which can raise the risk of cardiovascular events, and recommends monitoring blood pressure during therapy. Regular excessive alcohol consumption is one of the known causes of hypertension.
So for a patient on oral undecanoate, alcohol is one more factor pressing on the same target. Home blood pressure measurement and an honest report to the doctor about drinking help to notice a problem in time.
Monitoring of Therapy and Alcohol
Regardless of the form, undecanoate therapy requires regular monitoring. The Endocrine Society guidelines (2018) recommend monitoring testosterone levels, hematocrit, PSA in the relevant age groups, and symptoms related to the urinary tract and sleep. Alcohol can affect several of these parameters.
- Hematocrit:dehydration after a feast relatively raises the reading.
- Liver tests:alcohol raises GGT and other enzymes, which complicates assessment.
- Lipids:heavy consumption raises triglycerides.
- Sleep:alcohol worsens obstructive apnea, which is taken into account during testosterone therapy.
- SHBG:chronic consumption and liver damage change the level of the binding protein and the interpretation of total testosterone.
So that the tests reflect the real state, it is better to abstain from alcohol for a few days before donating blood and to come in a stable state of hydration. Specific requirements should be clarified with the laboratory.
The EASL clinical guidelines (2018) on alcoholic liver disease remind us that prolonged excessive alcohol consumption is the leading cause of chronic liver damage. For patients who receive hormone therapy for years, the condition of the liver is an important part of the overall health picture.
If a patient notices that they are drinking alcohol more often or more than they plan to, this is worth discussing with the doctor separately. Treating excessive alcohol consumption can improve both hormonal status and the effectiveness of the therapy.
Editorial Conclusions
Undecanoate is almost always used in a medical context, so the question of alcohol is a question of the safety of treatment and the accuracy of monitoring, rather than of “compatibility” in the narrow sense.
For the injectable form, the most important moment is the day of the procedure and the observation after it; for the oral form, it is blood pressure and a stable regimen of taking it with food.
Excessive alcohol consumption in itself lowers testosterone, so an honest conversation with the doctor about drinking helps to correctly establish the diagnosis and choose the treatment.
We also advise reading our materials on the causes of functional hypogonadism, on preparing for hormone tests, and on blood pressure control during testosterone therapy.
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Emanuele MA, Emanuele NV. Alcohol's effects on male reproduction. Alcohol Health Res World. 1998;22(3):195–201.
- Endo Pharmaceuticals. Aveed (testosterone undecanoate) injection. Prescribing information. U.S. Food and Drug Administration.
- Bayer. Nebido (testosterone undecanoate) 1000 mg/4 ml solution for injection. Summary of Product Characteristics.
- Jatenzo (testosterone undecanoate) oral capsules. Prescribing information. U.S. Food and Drug Administration.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154–181.
- Nieschlag E, Behre HM, Nieschlag S (eds). Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
